Table 5. Baseline Characteristics According to VFA.
| VFA |
P | ||
|---|---|---|---|
| < 100 cm2 | ≥ 100 cm2 | ||
| N | 44 | 30 | |
| Backgrounds | |||
| Sex (N) | |||
| Male/female | 18/26 | 8/22 | 0.23a |
| Age (years) | |||
| Median (IQR) | 68.5 (61.8 - 72.3) | 71.0 (66.5 - 76.5) | 0.04b |
| < 70/≥ 70 years (N) | 26/18 | 11/19 | 0.10a |
| Smoking status | |||
| NS/Ex, CS | 10/34 | 5/25 | 0.57a |
| Histology | |||
| Non-SQ/SQ | 33/11 | 22/8 | 1.00a |
| EGFR mutation | |||
| (+)/(-) or NA | 6/38 | 6/24 | 0.53a |
| PD-L1 status | |||
| ≥ 50%/1-49%/< 1%/NA | 7/9/3/25 | 6/6/5/13 | 0.49a |
| ECOG-PS | |||
| 0 - 1/2/3 | 33/9/2 | 20/7/3 | 0.57a |
| Metastatic sites | |||
| < 3/≥ 3 | 24/20 | 11/19 | 0.16a |
| BMI | |||
| Median (IQR) | 20.8 (18.0 - 22.8) | 24.8 (23.0 - 27.3) | < 0.01a |
| VFA (cm2) | |||
| Median (IQR) | 36.4 (18.1 - 57.3) | 139.5 (119.5 - 165.9) | < 0.01a |
| Treatment | |||
| ICI regimen (N) | |||
| Nivo/Pem/Atezo | 37/7/3 | 23/5/2 | 1.00a |
| Previous treatment (N) | |||
| Anti-angiogenic drug | 23 | 21 | 0.24a |
| Radiotherapy | 8 | 11 | 0.10a |
| Further line treatment (N) | 19 | 18 | 0.24a |
| ICI efficacy | |||
| CR/PR/SD/PD/NE | 3/6/6/26/3 | 0/2/9/17/1 | |
| ORR (%) (95%CI) | 20.5 (9.8 - 35.3) | 6.7 (0.8 - 22.1) | 0.18a |
| DCR (%) (95%CI) | 34.1 (20.5 - 49.9) | 36.7 (19.9 - 56.1) | 0.81a |
| Laboratory data | |||
| NLR | |||
| Median (IQR) | 3.13 (2.28 - 4.92) | 3.00 (1.88 - 4.42) | 0.72b |
| ≤ 5/> 5 (N) | 33/11 | 24/6 | 0.78a |
| Albumin (g/dL) | |||
| Median (IQR) | 3.5 (3.2 - 3.9) | 3.6 (3.2 - 3.9) | 0.68b |
| ≥ 3.5/< 3.5 g/dL (N) | 25/19 | 20/10 | 0.47a |
aFisher’s exact test. bMann-Whitney U test. Atezo: atezolizumab; BMI: body mass index; CI: confidence interval; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; Ex: ex-smoker; ICI: immune-checkpoint inhibitors; IQR: interquartile range; NE: not evaluated; Nivo: nivolumab; NLR: neutrophil-to-lymphocyte ratio; NS: non-smoker; ORR: overall response rate; PD: progressive disease; PD-L1: programmed cell death ligand 1; Pem: pembrolizumab; PR: partial response; SD: stable disease; SQ: squamous cell carcinoma; TPS: tumor proportion score; VSR: visceral to subcutaneous adipose tissue area ratio.